Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
2017 · New England Journal of Medicine · 5,655 citations
https://doi.org/10.1056/nejmoa1707447
J
John M. Rossi
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
142
Papers
16.7K
Citations
34
h-index
67
i10-index
John M. Rossi is an academic researcher from Université de Bordeaux. The author has contributed to research in topics: CAR-T cell therapy research & Biosimilars and Bioanalytical Methods & Lymphoma Diagnosis and Treatment. The author has an h-index of 34, co-authored 121 publications.
Papers by this author
worksKTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study
2021 · The Lancet · 721 citations
https://doi.org/10.1016/s0140-6736(21)01222-8
Preinfusion polyfunctional anti-CD19 chimeric antigen receptor T cells are associated with clinical outcomes in NHL
2018 · Blood · 334 citations
https://doi.org/10.1182/blood-2018-01-828343
Tumor immune contexture is a determinant of anti-CD19 CAR T cell efficacy in large B cell lymphoma
2022 · Nature Medicine · 183 citations
https://doi.org/10.1038/s41591-022-01916-x
Preliminary Results of Prophylactic Tocilizumab after Axicabtageneciloleucel (axi-cel; KTE-C19) Treatment for Patients with Refractory,Aggressive Non-Hodgkin Lymphoma (NHL)
2017 · Blood · 178 citations
https://doi.org/10.1182/blood.v130.suppl_1.1547.1547
A Phase 2 Multicenter Trial of KTE-C19 (anti-CD19 CAR T Cells) in Patients With Chemorefractory Primary Mediastinal B-Cell Lymphoma (PMBCL) and Transformed Follicular Lymphoma (TFL): Interim Results From ZUMA-1
2016 · Blood · 27 citations
https://doi.org/10.1182/blood.v128.22.998.998
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat